CN102177141B - 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 - Google Patents
作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 Download PDFInfo
- Publication number
- CN102177141B CN102177141B CN200980140385.9A CN200980140385A CN102177141B CN 102177141 B CN102177141 B CN 102177141B CN 200980140385 A CN200980140385 A CN 200980140385A CN 102177141 B CN102177141 B CN 102177141B
- Authority
- CN
- China
- Prior art keywords
- pyrrolidinyl
- benzimidazol
- benzimidazole
- ethynyl
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCN(C)C(*)=C Chemical compound CCN(C)C(*)=C 0.000 description 11
- NMJVWDZFUZKNHA-UHFFFAOYSA-N Nc(ccc(C(CCl)=O)c1)c1N Chemical compound Nc(ccc(C(CCl)=O)c1)c1N NMJVWDZFUZKNHA-UHFFFAOYSA-N 0.000 description 2
- NLJXQGWSRFKTIV-PMACEKPBSA-N C(C1)CN[C@@H]1c1nc2cc(C#Cc(cc3)cc4c3[nH]c([C@H]3NCCC3)n4)ccc2[nH]1 Chemical compound C(C1)CN[C@@H]1c1nc2cc(C#Cc(cc3)cc4c3[nH]c([C@H]3NCCC3)n4)ccc2[nH]1 NLJXQGWSRFKTIV-PMACEKPBSA-N 0.000 description 1
- DOQQUBLUZQAZSQ-UIOOFZCWSA-N CC(C)(C)OC(N(CCC1)[C@@H]1c1nc(cc(cc2)-c3cnc(-c4c5nc([C@H](CCC6)N6C(OC(C)(C)C)=O)[nH]c5ccc4)[o]3)c2[nH]1)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1c1nc(cc(cc2)-c3cnc(-c4c5nc([C@H](CCC6)N6C(OC(C)(C)C)=O)[nH]c5ccc4)[o]3)c2[nH]1)=O DOQQUBLUZQAZSQ-UIOOFZCWSA-N 0.000 description 1
- OMFDXFZGPZVKPG-AWEZNQCLSA-N CC(C)(C)OC(N(CCC1)[C@@H]1c1nc(ccc(C(CN)=O)c2)c2[nH]1)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1c1nc(ccc(C(CN)=O)c2)c2[nH]1)=O OMFDXFZGPZVKPG-AWEZNQCLSA-N 0.000 description 1
- IXXAJHQVQVSIRJ-WQVCFCJDSA-N CC(C)(C)OC(N([C@H](C1)[C@H]1C1)[C@@H]1c1nc(cc(cc2)C#C)c2[n-]1)=O Chemical compound CC(C)(C)OC(N([C@H](C1)[C@H]1C1)[C@@H]1c1nc(cc(cc2)C#C)c2[n-]1)=O IXXAJHQVQVSIRJ-WQVCFCJDSA-N 0.000 description 1
- PTEZWVYFPGDCKB-UHFFFAOYSA-N CC(C)(C)OC(N1C(C2)C2CC1)=O Chemical compound CC(C)(C)OC(N1C(C2)C2CC1)=O PTEZWVYFPGDCKB-UHFFFAOYSA-N 0.000 description 1
- SHRWLTDGUBGLPL-CJNGLKHVSA-N CC(C)(C)OC(N1C2=[I][C@@H]2C[C@H]1c1nc2cc(B3OC(C)(C)C(C)(C)O3)ccc2[nH]1)=O Chemical compound CC(C)(C)OC(N1C2=[I][C@@H]2C[C@H]1c1nc2cc(B3OC(C)(C)C(C)(C)O3)ccc2[nH]1)=O SHRWLTDGUBGLPL-CJNGLKHVSA-N 0.000 description 1
- IBJHTRHQPVRVKQ-CGLAOXQSSA-N CC(C)C(C(N([C@H](CC1)C1C1)[C@@H]1C1N(C)c(cc(cc2)-c3cccc(Oc(cc4)cc5c4[nH]c([C@H](C[C@@H](C)[C@H]4C)N4C([C@H](C(C)C)NC(OC)=O)=O)n5)c3)c2N1)=O)NC(OC)=O Chemical compound CC(C)C(C(N([C@H](CC1)C1C1)[C@@H]1C1N(C)c(cc(cc2)-c3cccc(Oc(cc4)cc5c4[nH]c([C@H](C[C@@H](C)[C@H]4C)N4C([C@H](C(C)C)NC(OC)=O)=O)n5)c3)c2N1)=O)NC(OC)=O IBJHTRHQPVRVKQ-CGLAOXQSSA-N 0.000 description 1
- DYECXWLWGXFUCR-ZBMHFKBZSA-O CC(CO[S+](C)C(C)(C)C)[C@@H](C(O)=O)NC(OC)=O Chemical compound CC(CO[S+](C)C(C)(C)C)[C@@H](C(O)=O)NC(OC)=O DYECXWLWGXFUCR-ZBMHFKBZSA-O 0.000 description 1
- STJQUSFKJADNSQ-UHFFFAOYSA-N CC(Nc(ccc(C(CCl)=O)c1)c1[N+]([O-])=O)=O Chemical compound CC(Nc(ccc(C(CCl)=O)c1)c1[N+]([O-])=O)=O STJQUSFKJADNSQ-UHFFFAOYSA-N 0.000 description 1
- CZPYIONABGXNGD-UHFFFAOYSA-N CCC(CC)C(C1)(C1NC(OC)=O)C(O)=O Chemical compound CCC(CC)C(C1)(C1NC(OC)=O)C(O)=O CZPYIONABGXNGD-UHFFFAOYSA-N 0.000 description 1
- YHZCTZGJKHNVQY-UHFFFAOYSA-N CCN(CC)C(C)C(O)=O Chemical compound CCN(CC)C(C)C(O)=O YHZCTZGJKHNVQY-UHFFFAOYSA-N 0.000 description 1
- NRQNEMBSIAIKFB-UHFFFAOYSA-N COc1c(ccnc2)c2ccc1 Chemical compound COc1c(ccnc2)c2ccc1 NRQNEMBSIAIKFB-UHFFFAOYSA-N 0.000 description 1
- CUJZTJAQHGZALD-ATMYOTEDSA-N C[C@@H](CC1)CN1[C@@H](C[C@H]1c2nc3cc(C#Cc(cc4)cc5c4[nH]c([C@H](C[C@@H](C4)N6CCCC6)N4C(Cc4ccccc4)=O)n5)ccc3[nH]2)CN1C(Cc1ccccc1)=O Chemical compound C[C@@H](CC1)CN1[C@@H](C[C@H]1c2nc3cc(C#Cc(cc4)cc5c4[nH]c([C@H](C[C@@H](C4)N6CCCC6)N4C(Cc4ccccc4)=O)n5)ccc3[nH]2)CN1C(Cc1ccccc1)=O CUJZTJAQHGZALD-ATMYOTEDSA-N 0.000 description 1
- ICWBMWXSUCXISY-SFVWDYPZSA-N C[C@@H](c1ccccc1)OC(C(c1ccccc1)Br)=O Chemical compound C[C@@H](c1ccccc1)OC(C(c1ccccc1)Br)=O ICWBMWXSUCXISY-SFVWDYPZSA-N 0.000 description 1
- KYNKAUUXUQOZSQ-GBXIJSLDSA-N C[C@H]([C@@H](C(O)=O)N1)OC1=O Chemical compound C[C@H]([C@@H](C(O)=O)N1)OC1=O KYNKAUUXUQOZSQ-GBXIJSLDSA-N 0.000 description 1
- WYYWXXFJXOJBBJ-UHFFFAOYSA-N N#Cc(nc1)c(cccc2)c2c1Br Chemical compound N#Cc(nc1)c(cccc2)c2c1Br WYYWXXFJXOJBBJ-UHFFFAOYSA-N 0.000 description 1
- BGNHODXRVHSTDK-UHFFFAOYSA-N Nc(cccc1Oc(cc2)ccc2Br)c1N Chemical compound Nc(cccc1Oc(cc2)ccc2Br)c1N BGNHODXRVHSTDK-UHFFFAOYSA-N 0.000 description 1
- BMVICXAUNDNFBI-HEVIKAOCSA-N O=C(Cc1ccccc1)N(CCC1)[C@@H]1c1nc2cc(-c(cc3)cc4c3nc([C@H](CCC3)N3C(Cc3ccccc3)=O)[nH]4)ccc2[nH]1 Chemical compound O=C(Cc1ccccc1)N(CCC1)[C@@H]1c1nc2cc(-c(cc3)cc4c3nc([C@H](CCC3)N3C(Cc3ccccc3)=O)[nH]4)ccc2[nH]1 BMVICXAUNDNFBI-HEVIKAOCSA-N 0.000 description 1
- NHDLHKVCFIVDPP-RXVVDRJESA-N O=C(Cc1ccccc1)N(C[C@H](C1)N2CCCC2)[C@@H]1c([nH]c1c2)nc1ccc2Br Chemical compound O=C(Cc1ccccc1)N(C[C@H](C1)N2CCCC2)[C@@H]1c([nH]c1c2)nc1ccc2Br NHDLHKVCFIVDPP-RXVVDRJESA-N 0.000 description 1
- ZLAKPURGNBLUCC-VUWPPUDQSA-N OC(C(c1ccccc1)N(CC1)C[C@H]1F)=O Chemical compound OC(C(c1ccccc1)N(CC1)C[C@H]1F)=O ZLAKPURGNBLUCC-VUWPPUDQSA-N 0.000 description 1
- GTKDBOZODTZEDK-QGZVFWFLSA-N OC(CC1)(CCN1[C@@H](C(O)=O)c1ccccc1)c1ccccc1 Chemical compound OC(CC1)(CCN1[C@@H](C(O)=O)c1ccccc1)c1ccccc1 GTKDBOZODTZEDK-QGZVFWFLSA-N 0.000 description 1
- RALBSRVEMPXONN-PQFLWIRSSA-N O[C@H](C[C@H]1c2nc3cc(C#Cc(cc4)cc5c4[nH]c([C@H](C[C@H](C4)O)N4C(Cc4ccccc4)=O)n5)ccc3[nH]2)CN1C(Cc1ccccc1)=O Chemical compound O[C@H](C[C@H]1c2nc3cc(C#Cc(cc4)cc5c4[nH]c([C@H](C[C@H](C4)O)N4C(Cc4ccccc4)=O)n5)ccc3[nH]2)CN1C(Cc1ccccc1)=O RALBSRVEMPXONN-PQFLWIRSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410267681.8A CN104072486B (zh) | 2008-08-07 | 2009-08-06 | 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8707808P | 2008-08-07 | 2008-08-07 | |
| US61/087,078 | 2008-08-07 | ||
| US61/087078 | 2008-08-07 | ||
| PCT/US2009/053019 WO2010017401A1 (en) | 2008-08-07 | 2009-08-06 | Bi-1h-benzimidazoles as hepatitis c virus inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410267681.8A Division CN104072486B (zh) | 2008-08-07 | 2009-08-06 | 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102177141A CN102177141A (zh) | 2011-09-07 |
| CN102177141B true CN102177141B (zh) | 2014-07-23 |
Family
ID=41314575
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980140385.9A Expired - Fee Related CN102177141B (zh) | 2008-08-07 | 2009-08-06 | 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 |
| CN201410267681.8A Expired - Fee Related CN104072486B (zh) | 2008-08-07 | 2009-08-06 | 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410267681.8A Expired - Fee Related CN104072486B (zh) | 2008-08-07 | 2009-08-06 | 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7906655B2 (enExample) |
| EP (1) | EP2318376B1 (enExample) |
| JP (1) | JP5599792B2 (enExample) |
| CN (2) | CN102177141B (enExample) |
| WO (1) | WO2010017401A1 (enExample) |
Families Citing this family (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2551352T3 (es) * | 2007-07-05 | 2015-11-18 | Array Biopharma, Inc. | Pirimido ciclopentanos útiles para el tratamiento de enfermedades inflamatorias o hiperproliferativas |
| BRPI0911260A2 (pt) * | 2008-04-15 | 2015-09-29 | Intermune Inc | composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos |
| GB0821913D0 (en) | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
| HK1203929A1 (en) * | 2008-12-03 | 2015-11-06 | 普雷西迪奥制药公司 | Inhibitors of hcv ns5a |
| JP2012510523A (ja) * | 2008-12-03 | 2012-05-10 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ５ａの阻害剤 |
| MX2011006332A (es) * | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| SG172353A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| EP2393359A4 (en) * | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | COMPOUND DIBENZIMIDAZOLE DERIVATIVES |
| US8314135B2 (en) * | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8420686B2 (en) | 2009-02-17 | 2013-04-16 | Enanta Pharmaceuticals, Inc. | Linked diimidazole antivirals |
| US8637561B2 (en) | 2009-02-17 | 2014-01-28 | Enanta Pharmaceuticals, Inc. | Linked diimidazole derivatives |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8188132B2 (en) * | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8426458B2 (en) | 2009-02-27 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Hepatitis C Virus inhibitors |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8507522B2 (en) | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102459165B (zh) * | 2009-04-15 | 2015-09-02 | Abbvie公司 | 抗病毒化合物 |
| AU2010249080A1 (en) | 2009-05-12 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| AU2014203349B2 (en) * | 2009-05-13 | 2014-11-27 | Gilead Sciences, Inc. | Antiviral compounds |
| AU2013202666B2 (en) * | 2009-05-13 | 2015-07-16 | Gilead Sciences, Inc. | Antiviral compounds |
| HUE036906T2 (hu) * | 2009-05-13 | 2018-08-28 | Antivirális vegyületek | |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2010253790A1 (en) | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
| AU2010253791A1 (en) * | 2009-05-29 | 2011-11-24 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| AU2012203474B2 (en) * | 2009-06-11 | 2014-09-18 | Abbvie Ireland Unlimited Company | Anti-Viral Compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| CA2737601C (en) * | 2009-06-11 | 2014-10-21 | Abbott Laboratories | Anti-viral compounds |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| IN2012DN00999A (enExample) | 2009-07-16 | 2015-04-10 | Vertex Pharma | |
| EP2462135A1 (en) | 2009-08-07 | 2012-06-13 | Janssen R&D Ireland | Bis-benzimidazole derivatives as hepatitis c virus inhibitors |
| RU2012112824A (ru) | 2009-09-03 | 2013-10-10 | Тиботек Фармасьютикалз | Производные бис-бензимидазола |
| MX2012002759A (es) | 2009-09-04 | 2012-04-30 | Glaxosmithkline Llc | Compuestos quimicos. |
| EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011038293A1 (en) * | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
| UA108211C2 (uk) * | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011066241A1 (en) * | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| US20110137633A1 (en) * | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Anti-viral compounds and methods of identifying the same |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8362068B2 (en) * | 2009-12-18 | 2013-01-29 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| CN102843909A (zh) | 2010-01-25 | 2012-12-26 | 埃南塔制药公司 | 丙型肝炎病毒抑制剂 |
| US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| CN102858157A (zh) * | 2010-03-04 | 2013-01-02 | 埃南塔制药公司 | 作为hcv复制的抑制剂的组合药物活性剂 |
| AR080676A1 (es) * | 2010-03-09 | 2012-05-02 | Schering Corp | Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| CA2794145A1 (en) * | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| WO2011119870A1 (en) * | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| WO2011127350A1 (en) | 2010-04-09 | 2011-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US20130296311A1 (en) * | 2010-05-28 | 2013-11-07 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| WO2011151620A1 (en) * | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
| AU2011260097B2 (en) | 2010-06-01 | 2015-01-22 | Summit (Oxford) Limited | Compounds for the treatment of clostridium difficile associated disease |
| EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
| CA2802067A1 (en) * | 2010-06-09 | 2011-12-15 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a protein |
| NZ605440A (en) * | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| JP2013531011A (ja) | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
| CA2803248A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| US8815849B2 (en) | 2010-07-26 | 2014-08-26 | Janssen R&D Ireland | Hetero-bicyclic derivatives as HCV inhibitors |
| WO2012021704A1 (en) | 2010-08-12 | 2012-02-16 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2012024363A2 (en) | 2010-08-17 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flaviviridae viral infections |
| BR112013004520A2 (pt) | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
| AU2014203655B2 (en) * | 2010-10-13 | 2016-07-07 | Abbvie Ireland Unlimited Company | Anti-viral compounds |
| CN103269586B (zh) | 2010-10-26 | 2015-07-15 | 普雷西迪奥制药公司 | 丙型肝炎病毒抑制剂 |
| US20150031884A1 (en) * | 2010-12-15 | 2015-01-29 | Abbvie Inc. | Anti-viral compounds |
| WO2012083043A1 (en) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| WO2012083164A1 (en) * | 2010-12-16 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2012158861A2 (en) | 2011-05-18 | 2012-11-22 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives |
| WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
| TW201317223A (zh) | 2011-07-26 | 2013-05-01 | Vertex Pharma | 噻吩化合物 |
| SMT201800087T1 (it) | 2011-09-16 | 2018-03-08 | Gilead Pharmasset Llc | Metodi per trattare hcv |
| WO2013098313A1 (en) | 2011-12-28 | 2013-07-04 | Janssen R&D Ireland | Hetero-bicyclic derivatives as hcv inhibitors |
| BR112014016007A8 (pt) | 2011-12-28 | 2017-07-04 | Janssen R&D Ireland | derivados de quinazolinona como inibidores de vhc |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| ES2802251T3 (es) | 2012-01-06 | 2021-01-18 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2827876A4 (en) | 2012-03-22 | 2015-10-28 | Alios Biopharma Inc | PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG |
| WO2014055069A1 (en) * | 2012-10-02 | 2014-04-10 | Presidio Pharmaceuticals, Inc. | Solid forms comprising an inhibitor of hcv ns5a, compositions thereof, and uses therewith |
| EA029081B9 (ru) | 2013-01-31 | 2018-09-28 | Джилид Фармассет Ллс | Комбинированный состав двух противовирусных соединений |
| RU2518369C1 (ru) * | 2013-02-07 | 2014-06-10 | Общество с ограниченной ответственностью "Интеллектуальный Диалог" | Алкил [2-(2-{5-[4-(4-{2-[1-(2-метоксикарбониламино-ацетил)-пирролидин-2-ил]-3н-имидазол-4-ил}-фенил)-бута-1,3-диинил]-1н-имидазол-2-ил}-пирролидин-1-ил)-2-оксо-этил]-карбамат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
| RU2507201C1 (ru) * | 2013-02-07 | 2014-02-20 | Александр Васильевич Иващенко | Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
| US20150065439A1 (en) | 2013-02-28 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP3021845A1 (en) | 2013-07-17 | 2016-05-25 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
| PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| PT3245198T (pt) | 2015-01-13 | 2020-06-16 | Novartis Ag | Derivados de pirrolidina como antagonistas de angiotensina ii tipo 2 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN113167802B (zh) | 2018-12-04 | 2025-02-07 | 百时美施贵宝公司 | 通过多同位素体反应监测使用样品内校准曲线的分析方法 |
| AU2022277904B2 (en) | 2021-05-21 | 2025-06-12 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
| KR20240012476A (ko) | 2021-05-21 | 2024-01-29 | 길리애드 사이언시즈, 인코포레이티드 | 지카 바이러스 저해제로서의 펜타사이클릭 유도체 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654451B1 (en) | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
| JPH08505854A (ja) | 1993-01-14 | 1996-06-25 | マガイニン ファーマシューティカルズ，インク． | 修飾された末端を有するアミノ酸及びペプチド |
| US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| AU1099000A (en) * | 1998-10-05 | 2000-04-26 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions for treating hepatitis c infections |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| AU2002228317A1 (en) * | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Benz-1,3-azole derivatives and their uses as heparanase inhibitors |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| HRP20100542T1 (hr) | 2005-09-16 | 2010-11-30 | Arrow Therapeutics Limited | Derivati bifenila i njihova uporaba za liječenje hepatitisa c |
| WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
| SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| WO2007138242A1 (en) | 2006-05-30 | 2007-12-06 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| WO2008014430A1 (en) | 2006-07-27 | 2008-01-31 | Emisphere Technologies, Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2094276A4 (en) | 2006-12-20 | 2011-01-05 | Abbott Lab | ANTIVIRAL COMPOUNDS |
| PT2114896E (pt) * | 2006-12-21 | 2015-11-04 | Peter Maccallum Cancer Inst | Compostos radio-protetores e métodos relacionados |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| EP2194981B1 (en) * | 2007-10-05 | 2011-11-23 | Université de Mons-Hainaut | Bisbenzimidazoles as antimalarial agents |
| NZ587323A (en) | 2008-02-12 | 2012-02-24 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| WO2009102694A1 (en) | 2008-02-12 | 2009-08-20 | Bristol-Myers Squibb Company | Heterocyclic derivatives as hepatitis c virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2008350334B2 (en) | 2008-02-13 | 2013-10-17 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis C virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2009
- 2009-08-05 US US12/536,362 patent/US7906655B2/en active Active
- 2009-08-06 CN CN200980140385.9A patent/CN102177141B/zh not_active Expired - Fee Related
- 2009-08-06 EP EP09791236.4A patent/EP2318376B1/en not_active Not-in-force
- 2009-08-06 CN CN201410267681.8A patent/CN104072486B/zh not_active Expired - Fee Related
- 2009-08-06 JP JP2011522250A patent/JP5599792B2/ja not_active Expired - Fee Related
- 2009-08-06 WO PCT/US2009/053019 patent/WO2010017401A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN104072486B (zh) | 2016-04-06 |
| JP5599792B2 (ja) | 2014-10-01 |
| JP2011530531A (ja) | 2011-12-22 |
| EP2318376A1 (en) | 2011-05-11 |
| WO2010017401A1 (en) | 2010-02-11 |
| US7906655B2 (en) | 2011-03-15 |
| CN104072486A (zh) | 2014-10-01 |
| CN102177141A (zh) | 2011-09-07 |
| US20100068176A1 (en) | 2010-03-18 |
| EP2318376B1 (en) | 2015-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102177141B (zh) | 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 | |
| CN102395579B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102143959B (zh) | 丙型肝炎病毒抑制剂 | |
| JP5612661B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| CN101998954B (zh) | 用作丙型肝炎病毒抑制剂的构象受限的联苯衍生物 | |
| CN102459250B (zh) | 丙型肝炎病毒抑制剂 | |
| JP5611959B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| TWI475019B (zh) | Ｃ型肝炎病毒抑制劑 | |
| CN103153986B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102712628B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102791693B (zh) | 丙型肝炎病毒抑制剂 | |
| TWI547480B (zh) | Ｃ型肝炎病毒抑制劑 | |
| JP5558556B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| ES2386590T3 (es) | Inhibidores del virus de la hepatitis C | |
| CN102015692A (zh) | 丙型肝炎病毒抑制剂 | |
| CN102459239A (zh) | 丙型肝炎病毒抑制剂 | |
| CN102448956A (zh) | 丙型肝炎病毒抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140723 Termination date: 20190806 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |